LogicBio has two platforms with the potential to enable groundbreaking advances in genetic medicine drug development
We are developing innovative approaches in gene editing and gene therapy. Our proprietary gene editing platform, GeneRide™, is designed to transform gene editing with higher levels of precision and durability, providing the flexibility to target different needs based on the disease. Our proprietary novel capsid platform, sAAVy™, is designed to enable the delivery of gene therapy and gene editing vectors with more potent expression and tissue specificity.
GeneRide™
Our proprietary GeneRide platform is designed to be a new approach to gene editing that harnesses a cell’s natural DNA repair process leading to durable therapeutic protein expression levels.
GeneRide supports the development of a new generation of genetic medicines designed to insert a corrective gene in the human genome with the goal of avoiding certain risks associated with other methods of gene therapy and gene editing.
The therapies developed based on our GeneRide platform are designed to use an engineered viral vector to deliver a corrective gene, known as a transgene, to the nuclei of a patient’s cells via a one-time infusion.
GeneRide has the potential to enable LogicBio to target many diseases that cannot be treated by current genetic medicines, including early onset indications. It could introduce the opportunity to develop therapies that can be administered in infancy, often before symptoms have a chance to progress.
sAAVy™
Our proprietary gene delivery capsid platform, sAAVy, is designed to overcome limitations with older-generation gene therapy capsids by bringing enhanced potency and tissue tropism with the potential for increased safety.
In collaboration with Children's Medical Research Institute, we are designing and selecting libraries of advanced adeno-associated virus (AAV) capsids using proprietary preclinical models. These synthetic capsids are developed through an iterative process using directed evolution, rational design, machine learning and innovative manufacturing.
We believe the sAAVy platform has the potential to support the development of treatments in a broad range of indications and tissues.
